Latest On Aspen Pharmacare Holdings Limited (APNHF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-09-21 06:04 EST | Dividend | A dividend of $3.42 has been announced on Aug 30, 2023. It will be paid Sep 26, 2023 with an ex-dividend date of Sep 21, 2023. | Neutral |  |
| 2023-03-04 06:38 EST | News | Aspen Pharmacare Holdings GAAP EPS of $0.60, revenue of $19.15B | N/A | |
| 2023-03-03 02:04 EST | News | Aspen Pharmacare Holdings Limited (APNHF) H1 2023 Earnings Call Transcript | N/A | |
| 2023-03-02 11:12 EST | News | Aspen Pharmacare Holdings Limited 2023 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-09-22 06:08 EST | Dividend | A dividend of $3.26 has been announced on Aug 31, 2022. It will be paid Sep 26, 2022 with an ex-dividend date of Sep 22, 2022. | Neutral | |
| 2022-09-02 09:58 EST | News | Aspen Pharmacare Holdings GAAP EPS of R$14.32, revenue of R$38.61B | N/A | |
| 2022-09-01 16:45 EST | News | Aspen Pharmacare Holdings Limited (APNHF) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-08-31 23:46 EST | News | Aspen inks deal with India’s Serum Institute to introduce four vaccines for Africa | N/A | |
| 2022-08-11 04:01 EST | News | Johnson & Johnson partner Aspen risks closure of COVID vaccine plant as orders dry up | N/A | |
| 2022-03-11 04:52 EST | News | Aspen Pharmacare Holdings Limited 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-03-11 04:52 EST | News | Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad on Interim 2022 Results - Earnings Call Transcript | N/A | |
| 2022-03-09 17:38 EST | News | Aspen Pharmacare Holdings reports 1H results | N/A | |
| 2022-03-09 00:38 EST | News | Johnson & Johnson inks deal with Aspen as COVID-19 vaccine makers focus on Africa | N/A | |
| 2021-09-22 06:13 EST | Dividend | A dividend of $2.62 has been announced on Sep 1, 2021. It will be paid Sep 27, 2021 with an ex-dividend date of Sep 22, 2021. | Neutral | |
| 2021-09-09 17:28 EST | News | Aspen Pharmacare hits 52-week high after unsolicited offers for pharma ingredient unit | N/A | |
| 2021-09-03 07:58 EST | News | Aspen Pharmacare Holdings Limited 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-09-03 07:58 EST | News | Johnson & Johnson vaccine shipments from Africa to Europe on hold | N/A | |
| 2021-09-02 12:00 EST | News | Aspen Pharmacare Holdings reports FY results | N/A | |
| 2021-09-02 12:00 EST | News | Aspen Pharmacare posts higher FY topline, shares rise | N/A | |
| 2021-09-02 12:00 EST | News | Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-01 16:10 EST | News | Johnson & Johnson in talks with Aspen Pharmacare for a licensing deal for COVID-19 shot | N/A | |
| 2021-03-13 12:42 EST | News | Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad Presents H1 2021 Results at JP Morgan Healthcare Conference (Transcript) | N/A | |
| 2021-03-13 09:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 18:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 23:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-11 06:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-10 13:53 EST | News | Aspen Pharmacare Holdings beats on revenue | N/A | |
| 2020-09-10 13:53 EST | News | Aspen Pharmacare Holdings Limited (APNHF) CEO Stephen Saad on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-31 08:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 17:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:18 EST | Financials | Company financials have been released. | Neutral | |
About Aspen Pharmacare Holdings Limited (APNHF):
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty, branded, and generic pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anaesthetics and muscle relaxants under the Anaesthetics brand; cytotoxic medicines under the Regional brand; and injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It is also involved in the contract and supply of chemical and biochemical active pharmaceutical ingredients and finished dose form pharmaceuticals for third parties. The company offers products in the form of oral solid dose, injectables, liquids, semi-solids, steriles, biologicals, and active pharmaceutical ingredients. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
General
- Name Aspen Pharmacare Holdings Limited
- Symbol APNHF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 9,069
- Last Split Factor1:3
- Last Split Date2016-04-19
- Fiscal Year EndJune
- Web URLhttp://www.aspenpharma.com
View More
Valuation
- Trailing PE 9.77
- Price/Sales (Trailing 12 Mt.) 1.69
- Price/Book (Most Recent Quarter) 0.94
- Enterprise Value Revenue 0.18
- Enterprise Value EBITDA 0.78
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 11%
- Return on Assets 5%
- Return on Equity 8%
- Earnings Per Share $0.97
- Revenue Per Share $0
- Gross Profit 19.32 billion
- Quarterly Earnings Growth 16.6%
View More
ESG Rating
Highlights
- Market Capitalization 4.51 billion
- Book Value Per Share $8.11
View More
Share Statistics
- Shares Outstanding 455.52 million
- Shares Float 371.75 million
- % Held by Insiders 1562%
- % Held by Institutions 57.9%
View More
Technicals
- Beta 0.86
- 52 Week High $10.5
- 52 Week Low $6.39
- 50 Day Moving Average 9.67
- 200 Day Moving Average 8.26
View More
Dividends
- Dividend Date 2017-10-09
- ExDividend Date 2018-10-04
- Dividend Per Share $0.23
- Dividend Yield 0%
View More
Aspen Pharmacare Holdings Limited (APNHF) Dividend Calendar:
APNHF's last dividend payment was made to shareholders on October 9, 2017.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Aspen Pharmacare Holdings Limited (APNHF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $0.17 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $0.15 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $0.14 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $9.21 billion | $0.13 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $9.21 billion | $0.19 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $9.6 billion | $0.18 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $9.84 billion | $0.20 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $10.35 billion | $0.21 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $10.35 billion | $0.18 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $10.95 billion | $0.20 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $10.95 billion | $0.30 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $8.25 billion | $0.28 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $8.04 billion | $0.19 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $9.9 billion | $0.19 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $9.9 billion | $0.22 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.22 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.07 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.07 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.24 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.26 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.25 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.25 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.23 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.24 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.32 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.32 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.20 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.21 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.20 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.22 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.22 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.22 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.18 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.18 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.17 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.17 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.19 | $0.00 |
Aspen Pharmacare Holdings Limited (APNHF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | N/A | 1.48 billion |
| Selling General Administrative | N/A | N/A | N/A | N/A | 2.41 billion |
| Gross Profit | N/A | N/A | N/A | N/A | 4.71 billion |
| Ebit | N/A | N/A | N/A | N/A | 1.82 billion |
| Operating Income | N/A | N/A | N/A | N/A | 1.82 billion |
| Income Tax Expense | 273 million | 273 million | 227.5 million | 227.5 million | 268 million |
| Total Revenue | N/A | N/A | N/A | N/A | 9.21 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 4.5 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -337.5 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 1.22 billion |
| Net Income Applicable to Common Shares | 1.27 billion | 1.27 billion | 1.02 billion | 1.02 billion | 1.31 billion |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Oct 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | 1.71 billion | 1.71 billion | -899.5 million | -899.5 million | -899.5 million |
| Net Borrowings | -4.45 billion | -4.45 billion | -1.26 billion | -1.26 billion | -1.26 billion |
| Total Cash Flow from Financial Activities | N/A | N/A | -1.28 billion | N/A | -1.28 billion |
| Change to Operating Activities | 704.5 million | 704.5 million | -608.5 million | -608.5 million | -608.5 million |
| Change in Cash | N/A | N/A | -889 million | N/A | -889 million |
| Total Cash from Operating Activities | 2.83 billion | 2.83 billion | 1.3 billion | 1.3 billion | 1.3 billion |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | 206.5 million | 206.5 million | 32 million | -136 million | 32 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 1.48 billion | 1.48 billion | 591.5 million | 223.5 million | 591.5 million |
| Capital Expenditures | N/A | N/A | 549.5 million | N/A | 549.5 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 61.75 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 55.96 billion |
| Other Current Liabilities | 2.96 billion | 2.96 billion | N/A | N/A | 2.33 billion |
| Total Assets | N/A | N/A | N/A | N/A | 117.71 billion |
| Common Stock | 1.86 billion | 1.86 billion | 1.9 billion | 1.9 billion | 1.87 billion |
| Other Current Assets | 180 million | 180 million | N/A | N/A | 5.69 billion |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | 8.51 billion | 8.51 billion | 9.85 billion | 9.85 billion | 7.57 billion |
| Other Assets | 2.91 billion | 2.91 billion | 3.18 billion | 3.18 billion | 1.88 billion |
| Cash | N/A | N/A | N/A | N/A | 5.95 billion |
| Total Current Liabilities | 20.09 billion | 20.09 billion | N/A | N/A | 22.71 billion |
| Other Stockholder Equity | 64.49 billion | 64.49 billion | 67.31 billion | 67.31 billion | 54.09 billion |
| Property, Plant & Equipment | 14.82 billion | 14.82 billion | 14.83 billion | 14.83 billion | 13.15 billion |
| Total Current Assets | 43.45 billion | 43.45 billion | N/A | N/A | 37.97 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 3.33 billion | 3.33 billion | -9.2 billion | -9.2 billion | -8.76 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | 31.47 billion |
| Inventory | 14.3 billion | 14.3 billion | N/A | N/A | 14.35 billion |
| Accounts Payable | 8.91 billion | 8.91 billion | N/A | N/A | 7.96 billion |
Aspen Pharmacare Holdings Limited (APNHF) Chart:
Aspen Pharmacare Holdings Limited (APNHF) News:
Below you will find a list of latest news for Aspen Pharmacare Holdings Limited (APNHF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aspen Pharmacare Holdings Limited (APNHF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Aspen Pharmacare Holdings Limited (APNHF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2009-01-16 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1454177/000101915509000061/0001019155-09-000061-index.htm |
| 2012-07-18 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1454177/000101915512000447/0001019155-12-000447-index.htm |
| 2014-01-28 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1454177/000119380514000129/0001193805-14-000129-index.htm |
| 2015-04-27 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1454177/000119380515000640/0001193805-15-000640-index.htm |
| 2015-08-27 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1454177/000119380515001424/0001193805-15-001424-index.htm |
| 2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1454177/000119380517003036/0001193805-17-003036-index.htm |
| 2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1454177/000119380519001743/0001193805-19-001743-index.htm |